News & Events

REYKJAVIK, ICELAND & BERN, SWITZERLAND – 4 June 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’), a clinical-stage biopharmaceutical company leading in epithelial biology, and AlveoliX, a pioneer in organ-on-chip technology, announce significant milestones in their collaboration to revolutionize ulcerative colitis (UC) treatment. The EpicoliX Project is supported by a grant of ~EUR1.4M from the Eureka Eurostars funding program, the Icelandic Technology Development Fund, and Innosuisse in Switzerland.

REYKJAVIK, ICELAND – 7 May 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has contributed to a book chapter in Macrolides as Immunomodulatory Agents, published in January.

REYKJAVIK, ICELAND – 10 April 2024 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

EpiEndo Pharmaceuticals has announced the recent appointments of Professor Bartolome Celli and Professor Fernando J. Martinez to its Scientific Advisory Board.

EpiEndo Pharmaceuticals is pleased to be celebrating its 10-year anniversary today.

REYKJAVIK, ICELAND – 2 November 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has initiated a healthy volunteer drug-drug interaction (DDI) clinical trial for lead compound, EP395.

REYKJAVIK, ICELAND – 23 October 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has completed its proof of pharmacology study for lead asset EP395 in healthy volunteers.

REYKJAVIK, ICELAND - 23 August 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic airway diseases, has contributed to a chapter in a key medical textbook, published this month.